KMTS

Business Context and Reporting Period

Kestra Medical Technologies, Ltd. (KMTS) is a commercial-stage medical device company focused on the Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD). The company leases the device to patients at risk of sudden cardiac arrest, billing third-party payors including Medicare and private insurers. This Form 10-Q covers the quarterly period ended July 31, 2025. The company completed its Initial Public Offering (IPO) in March 2025, raising approximately $215.8 million in net proceeds.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 52% year-over-year, driven by a 54% increase in the number of patients using the ASSURE WCD and improved collection efforts from a 55% larger revenue cycle management team.
• Expense Expansion: Selling, General, and Administrative (SG&A) expenses surged 75% to $33.7 million, primarily due to a $9.3 million increase in personnel costs to support commercial growth and $2.0 million in public company transition costs (legal, accounting, professional fees).
• Profitability: While gross profit doubled (111% increase) due to better equipment utilization and lower per-patient costs, the Net Loss widened by 27% to $25.8 million due to the significant ramp-up in operating expenses.
• Non-Cash Items: Other income included a $2.9 million gain from the change in fair value of warrant liabilities, partially offsetting the operating loss.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes existing cash ($201.2 million) and revenue will fund operations for at least the next 12 months. However, the company expects to continue incurring net losses as it scales its commercial organization.
• Debt Covenants: The company holds a $45.0 million term loan (Term Loan 2024). It failed to meet revenue milestones for follow-on tranches in late 2024 but amended the agreement in February 2025 to allow an additional $15.0 million draw if a $60.0 million trailing twelve-month revenue run rate is achieved by July 31, 2026.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of July 31, 2025, due to material weaknesses. These include insufficient accounting/IT resources, lack of controls over complex transactions (e.g., lease classification), and deficiencies in IT general controls (segregation of duties, change management).
• Risks: Key risks include the ability to maintain regulatory approvals, reimbursement availability, scaling manufacturing, and the potential need for additional equity or debt financing if growth plans require more capital than currently projected.

Investor Verification Checklist

• Remediation of Material Weaknesses: Verify the progress of hiring additional accounting/IT personnel and implementing controls to address the identified internal control failures.
• Debt Covenant Compliance: Monitor the company's ability to achieve the $60.0 million trailing twelve-month revenue threshold required to access the remaining $15.0 million tranche of its term loan.
• Reimbursement Rates: Confirm that reimbursement realization rates remain stable as the patient base expands, as this is critical to maintaining the improved gross margins.
• Cash Burn Rate: Track the trajectory of operating cash burn against the $201.2 million cash balance to validate the 12-month liquidity runway.
• Warrant Liability Volatility: Monitor the fair value of warrant liabilities, as fluctuations significantly impact reported net income/loss without affecting cash flow.